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ABSTRACT 
Neuroendocrine abnormalities are common in Parkinson’s disease (PD) and they 
include disruption of circadian rhythms, disturbances of glucose and bone 
metabolism, insulin resistance and body weight changes. They have been 
associated with multiple non-motor symptoms inof PD and have important clinical 
implications. Some of the underlying mechanisms have been implicated in the 
pathogenesis of PD and they appear to be promising research targets for the 
development of potential disease biomarkers of the disease and neuroprotective 
therapies.  
Here we provide a system-based review of the clinically relevant neuroendocrine 
abnormalities clinically relevantobserved in Parkinson’s disease in order to increase 
the appreciation and awareness of these disturbancesamongst clinicians by 
clinicians. We discuss the pathophysiological mechanisms, associated clinical 
implications, and pharmacological and non-pharmacological therapeutic interventions 
recommended based on the current evidence. We also review the recent advances 
achieved in theis field, focusing onin the potential targets for development of 
neuroprotective drugs in Parkinson’s disease and suggest future areas for research.     
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INTRODUCTION 
Parkinson’s disease (PD) is a common neurodegenerative condition characterised by 
both motor and non-motor symptoms (NMS). Whilst the classic motor features are 
attributable to nigrostriatal dopaminergic cell loss, the spectrum of NMS has reflect a 
more complex aetiology with underlyingwhich includes numerous neuroendocrine 
and metabolic abnormalities implicated.  
Neuroendocrine abnormalities in PD are important for several reasons[DB3]: 
- They are relatively common, mainly seen in advanced stages of PD , and 
associated with multiple NMS.  
- They appear to be an integral feature of PD and not simply secondary to 
disruption of other physiological processes. Recent advances have shed light 
on their underlying pathophysiology and the relationship to PD, although 
there remain important questions regarding the effect of neurodegeneration in 
PD on the neuroendocrine axes. 
- A better appreciation of the neuroendocrine abnormalities in PD and their has 
important clinical implications may allow more tailored clinical assessment 
and offer the opportunity for and highlights potential symptomatic therapeutic 
interventions that should be part of the routine clinical assessment in PD 
patients.  
- Some of the neuropeptides and hormones involved are easy to measure and 
quantify in various body fluids (blood/urine/saliva). Altered concentrations 
may correlate with disease severity and play a role in disease progression 
and pathogenesis. As such, they could represent potential peripheral 
biomarkers of disease state.  
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- Importantly, elements of the neuroendocrine system they could be the basis 
for the future development of much needed targeted therapies for NMS and 
neuroprotective treatments in PD.  
This review does not cover all the endocrine systems or metabolic abnormalities 
systems known to be altered disrupted in PD, but provides a system-based overview 
of only those in which there have been recent advances with in terms of the clinical 
or therapeutic implications. We discuss the current evidence, therapeutic 
recommendations and future areas for research for each of these neuroendocrine 
and metabolic disorders clinically relevant in PD.    
 
SEARCH STRATEGY 
A Pubmed/Medline search was performed for articles published in English between 
January 1990-December 2015. We combined searches with using ‘Parkinson’s 
disease’ using theand the  keywords ‘neuroendocrine’, ‘circadian disorder’, 
‘suprachiasmatic nucleus’, ‘hypothalamus’, ‘melatonin’, ‘pineal gland’, ‘diabetes’, 
‘insulin resistance’, ‘glucose intolerance’, ‘body weight’, ‘feeding behaviour’, ‘leptin’, 
‘ghrelin’, ‘osteoporosis’, ‘bone mineral density’ and ‘vitamin D’. Reference lists were 
manually checked to include capture any additional articles. The final list of 
references was generated based on the relevance of the articles to the aim of this 
review.    
 
CIRCADIAN RHYTHM AND SLEEP DISORDERS 
Circadian (daily) rhythms are present in almost all physiologic functions, of which the 
sleep-wake cycle is the most apparent. The system responsible for this near 24-hour 
rhythm is composed of central and peripheral oscillators . (Figure 1). The central 
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biological master clock is located in the suprachiasmatic nuclei us (SCN) of the 
anterior hypothalamus.1 Melatonin is the most important endogenous entraining 
agent and is produced by the pineal gland during darkness. It is considered to be as 
thea reliable key output from the endogenous clock conveying the signal from the 
SCN.2  
It is well accepted that coordination of circadian rhythms is an essential element of 
optimal physical and mental health 3 and its disruption has been associated with 
metabolic disturbances,4 disorders of the immune system,5 increased cancer risk,6 
renal dysfunction,7 cardiovascular disease,8 impaired cognition, psychiatric and mood 
disorders.9 10[DB4] Growing evidence suggests that alterations of the circadian system 
in PD patients of PD might contribute not only to sleep-wake cycle dysregulation but 
also to other NMS.   
 
 
Circadian abnormalities in PD  
Daily fluctuations of symptoms and loss of physiological circadian oscillations of 
some body functions have beenare well recognized in PD patients with PD:.  
- Motor function:. Actigraphic studies have demonstrated a disruption of the 
physiological motor pattern, with increased activity at bedtime and reduced 
motor performance during the day in patients with PD which correlates with 
disease severity[DB5].11 12 Moreover, PD patients have showndisplay 
worsening of their motor symptoms with diminished motor response to 
levodopa therapy in the evening, unexplained by pharmacokinetic factors.13 14  
- Non-motor function:. Cardiovascular circadian rhythms are also affected in 
PD, with reduced heart rate variability 11 15 16 and reversal of the circadian 
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blood pressure profile with nocturnal hypertension.17 18 A lower body core 
temperature and reduced nocturnal fall in body temperature have also been 
reported, suggesting a circadian disruption of thermoregulation.19  
- Sleep: Though a review of the sleep disorders in PD is out ofbeyond the 
scope of this article, they are very common and include sleep fragmentation, 
insomnia, sleep fragmentation, REM sleep behavioural disorders, restless 
legs syndrome, and sleep attacks and excessive daytime 
sleepiness[DB6].20[DB7] It is well accepted that they have a multifactorial origin 
including re-emergence of motor and NMS at nightovernight, nocturia, side 
effects of the dopaminergic and other medications, and degeneration of the 
regulatory mechanisms of the sleep-wake cycle secondary to the disease 
process. In addition, a disruption toof the circadian sleep-wake cycle is likely 
to contribute to some extent to these symptoms. [DB8]Orexin neurons in the 
lateral hypothalamus exert a wake-promoting effect and form a mutually 
inhibitory circuit with the sleep-promoting neurons of the hypothalamic 
ventrolateral preoptic area regulating the sleep-wake cycle.21 Some of the 
sleep disturbances in PD patients resemble those of narcolepsy, a sleep-
wake disorder characterized by loss of orexin neurons with undetectable CSF 
orexin levels.22 Studies assessing CSF orexin levels in PD have shown 
conflicting results, with normal levels in spinal CSF analysis 23 24 but low 
intraventricular CSF levels in patients with advanced PD,25 emphasizing the 
importance of  CSF sampling site and stage of disease in interpreting  orexin 
involvement in PD. In addition, two additional pathological studies have 
confirmed thate damage occurs to the orexin system in PD patients, showing 
a severe reduction of orexin cells in the lateral hypothalamus correlating with 
disease severity.26 27 It seems plausible that altered orexin signalling 
contributes to excessive daytime sleepiness and other sleep disorders in PD 
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patients, though the clinical impact of the orexin system damage still needs to 
be determined. 28 29  
- PD pathophysiology: Disrupted circadian rhythms are likely to have severe 
consequences on the systemic health in patients with PD., Band based on 
animal models, it has been suggested that alterations in the circadian system 
might accelerate the pathological processes underlying PD.30[DB9][DB10]  
 
 
Markers of circadian activity 
The different elements of the circadian system have not been systematically 
assessed in PD and the neuroanatomical site of disruption remains unknown. By 
contrast, several studies have assessed circadian activity in patients with PD using 
different peripheral markers.  
- Clock genes: At a molecular level, circadian rhythms are regulated by 
several clock genes forming a set of interlocking transcription-translation 
feedback loops. Tand their pattern of expression has been proposed as a 
peripheral marker of circadian activity.31 A few studies have shown 
abnormalities in the expression of various clock genes in peripheral blood ofin 
patients with PD including a reduction in the expression [DB11]of BmalMAL1 
correlated with disease severity,32 33 BmalMAL2,34 and altered promoter 
methylation of NpasPAS2 genes.35  
- Melatonin: As there is no pineal storage, plasma circulating melatonin levels 
faithfully reflects pineal activity and therefore it isare considered a good 
biological marker of the circadian system.2 Several studies have shown 
abnormalities in the pattern of melatonin secretion in patients with PD. A 
phase advance of the nocturnal plasma[DB12] melatonin and a decrease of the 
9 
 
night-to-daytime ratio secretion of melatonin have been shown in small 
studies[DB13]. 36 37 A more recent study with strict protocols on environmental 
conditions and behaviour to control the effects of exogenous variables 
showed additional diminished amplitude and reduced 24-hour area under the 
curve melatonin secretion in 20 PD patients on dopaminergic therapies with a 
strong correlation with excessive daytime sleepiness.38  Similar reduction in 
melatonin levels correlated with various alterations in sleep architecture was 
also reported in 30 newly diagnosed PD patients in comparison to healthy 
controls.33 However, in both studies, melatonin secretion abnormalities did not 
show any association with disease duration, disease severity or dopaminergic 
therapy. Given the possible link between dopamine and the regulation of 
melatonin, 13 drug-naïve patients, 16 medicated PD patients and 28 age-
matched controls underwent serial salivary melatonin sampling[DB14].39 This 
showed an increase in melatonin in treated PD patients, though paradoxically 
this was associated with more circadian disruption, raising the possibility that 
dopaminergic replacement therapy and not neurodegeneration wais the 
underlying responsible mechanism[DB15].  
 
These preliminary data suggest that impairment of the circadian system is an early 
feature of the disease, though no firm conclusions regarding the underlying 
mechanism can be made. T and these results should be interpreted with caution due 
to the impact of exogenous factors such as dopaminergic therapy as a potential 
confounder[DB16][DB17]. 
 
Therapeutic implications  
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- Melatonin. Downing et al 40 compared the administration of melatonin 5 or 50 
mg/day of melatonin toversus placebo for a period of two2 weeks in a 
randomized controlled cross-over trial in 40 PD patients assessing nocturnal 
sleep, daytime sleepiness and daytime functioning. Actigraphy showed a 
minimal increment (10 minutes) in total night-time sleep in the group treated 
with melatonin 50 mg/day but subjective improvement of thein sleep quality in 
the group on lower dosestaking 5mg/day in comparison tocompared with 
placebo. Another study with 18 PD patients randomized to melatonin 3 
mg/day or placebo for four weeks showed similar results with significant 
improvement of thein subjective quality of sleep but no significant differences 
on polysomnography between groups.41 Based on these results, a consensus 
from the Movement Disorder Society concluded that there wais insufficient 
evidence on the efficacy of melatonin for the treatment of insomnia in PD.42 
Further studies with larger samples and careful protocol design are 
warranted[DB18].  
- Bright light therapy:. Though the exact mechanism remains elusive, it has 
been postulated that bright light therapy might restore circadian rhythmicity as 
it has demonstrated efficacy in the treatment of mood disorders.43 Although 
Though in PD iit has only been assessed in a few PD studies, it has shown 
promising results on sleep, mood and motor function. 44 though fFurther 
studies with standardized protocols and rigorous designs are required to 
replicate these results.    
 
DIABETES AND GLUCOSE METABOLISM  
Though tThe potential association between PD and type 2 diabetes (T2DM) has long 
been recognised,45 but it has only recently been the subject of more attention.46  
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Epidemiological studies 
The prevalence of glucose intolerance has been estimated to be as high as 80% in 
PD patients in classical studies,45 although more recent epidemiological data have 
provided remain conflicting data.  A recent meta-analysis of case-control studies 
reported a negative association (OR = 0.75 [95%CI 0.58-0.98]) 47 although still 
observed that 2.9% of PD patients had a diagnosis of diabetes compared to only 
1.6% ion the non-PD population. Case-control studies are potentially prone to 
selection bias towards individuals attending specialist clinics, and also cannot 
exclude later development of either PD or diabetes among studied patients, therefore 
the evidence they provide in establishing a consistent association may be less 
robust. Indeed these results contrast with a meta-analysis of findings from 
prospective studies, where pre-existing T2DM was indeed found to be a risk factor 
for future PD (RR = 1.26 [95%CI 1.03-1.55]; p <0.0001)..48 49 Some of the conflicting 
results might also be explained by the heterogeneity between studies in terms ofthe 
case ascertainment of both conditions, and the potential for misclassification with 
respect to certainty of both diagnosis of both conditions. PD and diabetes, and 
alsoSome studies may also fail to take intonot account for the potential role of 
diabetices medications, and though other environmental and ethnic factors might 
alsowhich could modulate the association in different populations.  
T2DM has not only been suggested to be a risk factor for PD, but it might also exert 
a modifying effect on PD phenotype and disease progression. A case-control study 
showed that PD patients with antecedent diabetes have more severe motor 
symptoms and higher scores on the Unified Parkinson’s Disease Rating Scale 
(UPDRS), requiring treatment with higher doses of levodopa.50 Clinical studies have 
shown that the presence of T2DM is associated with specific phenotypes, including 
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greater postural instability, gait difficulties and cognitive impairment.51-53 This 
association is clinically relevant as axial motor symptoms and cognitive impairment 
are generally less responsive to dopaminergic therapies and are a major cause of 
disability. The hypothesis that this lack of therapeutic response to treatment is 
secondary to other neurotransmitter involvement is supported by the fact that 
phenotypic variability was not explained by differences in nigrostriatal dopaminergic 
denervation on [11C]dihydrotetrabenazine PET scans in PD patients with and without 
T2DM.51        
 
Pathophysiological mechanisms 
Though the exact mechanism whereby T2DM constitutes a risk or modifying factor 
for PD remains unknown, rRecent studies have begun to provided evidence in an 
attempt to elucidate the underlying pathways:.  
- Cerebrovascular disease:. One might argue that the increased prevalence 
of vascular pathology and vascular parkinsonism in patients with T2DM might 
in part account for these findings. However, the association between PD and 
T2DM in epidemiological studies remained significant after adjustment for 
vascular risk factors and exclusion of participants with clinical 
[DB19]cerebrovascular disease.48 49 Other MRI studies using MRI[DB20] 
assessments of the presence of cerebrovascular disease and leukoaraiosis 
showed no differences between groups of PD patients with or without 
diabetes to explain the different phenotypes.51  
- Dopaminergic medication:. The effect of some of the anti-PD medications 
on glucose metabolism has been suggested as a potential confounding 
factor, as since evidence suggests a reciprocal regulation between insulin 
and brain dopaminergic activity. Chronic treatment with levodopa has been 
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shown to induce decreased glucose tolerance, hyperglycaemia and 
hyperinsulinaemia.54 55 On the other hand, bromocriptine increases insulin 
sensitivity and improves glycaemic control, and is licensed for the treatment 
of diabetes.56 However, reduced insulin-mediated glucose uptake,54 and 
inhibition of early insulin secretion and long term hyperinsulinaemia and 
hyperglycaemia after glucose loading 57 have also been found in samples of 
drug-naïve patients, supporting the hypothesis that abnormal insulin 
signalling and glucose metabolism predate dopaminergic treatment in PD 
patients.  
- Cellular and molecular biology:. There is growing evidence from various 
areas of research suggesting a common link between diabetes and PD and iIt 
has been hypothesised that aberrant insulin signalling might ultimately lead to 
insulin resistance and diabetes, and put an individuals at increased risk for 
PD. Mitochondrial dysfunction, neuroinflammation, increased endoplasmic 
reticulum stress, abnormal protein aggregation and metabolic abnormalities 
are common to both diabetes and PD, suggesting a pathophysiological link.46 
58  
 
 
Therapeutic implications 
The common pathophysiological mechanisms shared by T2DM and PD are 
particularly relevant as they may lead to more effective treatments or disease 
modifying therapies fwhich target both of these conditions. or PD and T2DM. A 
prospective observational study showed that treatment with metformin combined with 
sulfonylureas might have a protective effect on the risk of developing PD in a 
Taiwanese cohort of diabetic patients.59 Special attention has focussed on the 
14 
 
potential neuroprotective properties of peroxisome proliferator activated receptor 
gamma (PPAR-γ) and its coactivator 1-α (PGC1α) due to its pivotal role in 
mitochondrial respiration and gluconeogenesis, and as potential target for 
neuroprotective agents in PD. PPAR-γ agonists thiazolidinediones, pioglitazone and 
rosiglitazone, have been successfully tested[DB21] for their neuroprotective potential in 
animal models of PD though their underlying mechanisms are still unclear[DB22].60 
The potential therapeutic effect of these drugs on PD was further supported by a 
retrospective cohort study which showed a 28% lower rate of developing PD in those 
diabetic patients treated with thiazolidinediones compared to other anti-diabetic 
drugs.61 These results prompted a large, multicentre, double-blind, placebo-
controlled clinical trial including 210 patients randomly assigned to 45mg/day 
pioglitazone, 15mg/day pioglitazone or placebo to assess the potential effect on PD 
patients. Results failed to show any significant benefit on motor symptoms measured 
by the UPDRS and the authors concluded that pioglitazone is unlikely to modify 
clinical progression in PD at the doses studied.62  
 
More promising are the preliminary clinical results shown by exenatide, a synthetic 
agonist for the glucagon-like peptide 1 (GLP1) receptor licensed for the treatment of 
diabetes, which has been evaluated as a neuroprotective agent in patients with PD 
(for a detailed description of potential mechanisms linking PD pathogenesis and 
GLP1 receptor stimulation, see review by Athauda and Foltynie). 63 An initial open 
label randomised controlled trial comparing 20 patients with PD treated with 
exenatide and 24 PD patients acting as controls showed a clinically relevant 
improvement in motor and cognitive domains in the treatment group after 12 
months.64 Further studies with larger samples are currently on going 
(ClinicalTrials.gov number NCT01971242).  
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BODY WEIGHT AND ENERGY METABOLISM 
Extensive research on the mechanisms controlling governing body weight, feeding 
behaviour and energy metabolism has provided insight into the complex interactions 
between the peripheral signals and the central nervous system. The classic concept 
of anatomically distinct ‘“satiety/feeding’” centres have been gradually replaced by a 
more complex model formed byencompassing a network of interconnected neurons 
of homeostatic and hedonic systems, receiving and integrating multiple orexigenic 
and anorexigenic signals from peripheral tissues, nutrients and other areas of the 
central nervous system. (Figure 2). 65-67  
 
Epidemiology 
The mechanisms regulating food intake might be involved implicated in other 
behaviours and brain functions including learning and memory, and thea positive 
association between obesity, brain atrophy and dementia is well recognized.68 A 
causal relationship between being overweight and PD is more controversial and 
results from prospective epidemiological studies are inconclusive.69 Some have 
shown a positive association of indices of obesity measured by body mass index 
(BMI) 70-72 and triceps skinfold thickness 73 with an increased risk of PD but these 
results have not been reproduced in other cohorts.74 75  
 
On the other hand, the inverse association is well recognized and unintentional 
weight loss has been consistently reported with PD (affecting approximately 50% of 
patients with PD). 71 76-78 A meta-analysis including 871 patients showed an overall 
reduction of 1.73kg/m2 in patients with PD in comparisoncompared with controls, with 
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a positive association with disease severity but not with disease duration.79 This 
weight loss carries important clinical implications as it seems to be associated with a 
more severe disease progression80 and to correlate inversely with health-related 
quality of life. 81 
Several mechanisms  have been proposed to explain the weight loss in PD, although 
it is likely that these are include intrinsic disease factors, as well as both peripheral 
and central mechanisms multiple, given the multifocal involvement of different 
systems in PD.82 
 
Parkinson’s disease intrinsic factors 
- Dopaminergic dysfunction:. Due to the relevant role of dopamine in 
regulation of the hedonic mechanisms of feeding behaviour,83 dopamine 
dysfunction producing anorexigenic signals in the hypothalamus has been 
proposed as one of the causes contributing to the weight loss in PD.  
- Levodopa:. Despite the fact that Though weight loss has been shown to be 
more prominent after levodopa treatment initiation in observational studies,84 
85 it seems that the levodopa requirement simply reflects disease severity. In 
addition, weight loss in PD has been well reported before treatment with 
dopaminergic therapies, 86 sometimes predating the onset of motor 
symptoms.77  
- Imbalanced energy expenditure/intake:. Reduced caloric intake secondary 
to motor (rigidity, impaired hand coordination) and gastrointestinal 
(dysphagia, reduced bowel motility, upper gastrointestinal symptoms) 
complications have been proposed as a factor of adriving the potential energy 
imbalance contributing to weight loss. However, several studies have 
demonstrated that weight loss occurs despite an increased energy intake in 
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patients with PD.77 86 Given the correlation between weight loss and disease 
severity,79 87 motor symptoms (tremor, rigidity) and motor complications 
(dyskinesias) could potentially increase the energy expenditure [DB23]at rest 
resulting in weight loss. However , other studies have demonstrated that the 
total daily energy expenditure is not higher in PD patients with weight loss 
comparing to PD patients without weight loss 88 and healthy controls,89 
arguing against the possibility that abnormally elevated energy expenditure 
contributes to weight loss in PD.  
 
Peripheral mechanisms of feeding behaviour regulation 
- Leptin:. Measurement of leptin 87 90 and other adipokines 91 have shown no 
statistically significant differences in patients with PD and weight loss 
compared to PD without weight loss and controls. Despite results showing a 
trend of reduced levels in PD patients overall, there is a correlationthis is 
correlated with BMI and, therefore it seems that this reduction of leptin levels 
is moremost likely a consequence reflectingreflects the reduced body fat 
tissue content rather than being a causal factor for weight loss.  
- Ghrelin:. More interesting results come from study of ghrelin. Ghrelin levels 
rise with prolonged fasting and fall rapidly after food ingestion, with an overall 
negative correlation with body weight. In PD patients, however, there is a 
lower plasma ghrelin concentration in those patients with lower BMI 92 and a 
reduction of the rising ghrelin levels after the postprandial fall in patients with 
PD and idiopathic RBD,93 suggesting  dysregulation of its secretion. SinceAs 
RBD is considered a putative pre-motor stage of PD, ghrelin has been 
proposed as a potential peripheral biomarker for early PD. 93 Recent studies 
demonstrated that ghrelin exerts a number of roles in other extra-
18 
 
hypothalamic tissues such as the(including the hippocampus and the 
mesolimbic dopaminergic system), and is implicated in learning and memory, 
reward behaviour, motivation, anxiety and depression.94 It also activates the 
dopaminergic nigrostriatal system by stimulating the dopaminergic neurons of 
the substantia nigra, increasing the dopamine turnover in the dorsal 
striatum.94 More importantly, ghrelin is reported to have neuroprotective 
properties in the nigrostriatal system in experimental animal models of PD.95 
Reduction of apoptosis, inflammation and enhancement of mitochondrial 
bioenergetics seem to mediate the neuroprotective effects of ghrelin in PD 
involving AMPK (5’ adenosine monophosphate-activated protein kinase) and 
PGC1α pathways at a molecular level.96 Interestingly, this regulatory pathway 
of mitochondrial function has also been suggested as a potential therapeutic 
target in neuroprotection for PD and T2DM 46 ( see ‘Diabetes and glucose 
metabolism’ above). Though these findings need to be replicated in humans, 
ghrelin appears a promising therapeutic target for disease neuroprotection 
and treatment of NMS such as body weight, apathy and depression. 
 
Central mechanisms of feeding behaviour regulation 
- Deep brain stimulation: . The role of the central regulatory hypothalamic 
mechanisms in weight disturbances in PD has recently attracted much 
attention in part due to the effects of deep brain stimulation (DBS) on body 
weight in PD. Rapid weight gain has been consistently reported in multiple 
studies ofin patients with PD after subthalamic nucleus (STN) DBS, which 
greatly exceeds the weight loss seen in medically treated patients.97-100 These 
effects have not been seen in patients with essential tremor undergoing DBS 
of the motor thalamus.101 Though vVarious mechanisms have been 
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postulated, buti itt seems that STN DBS may induce changes in the 
regulatory mechanism of the hypothalamus with normalization of energy 
metabolism.102 These effects seem target dependant, being more marked 
when in bilateral STN stimulation (compared to unilateral STN stimulationin 
comparison to unilateral stimulation,103 in the STN rather than theor globus 
pallidus internus (GPi) stimulation 104) and with more medial position of the 
electrodes in STN DBS.105 [DB24]A dDirect current diffusion of electrical current 
of the DBSfrom the site of stimulation to the hypothalamic nuclei is unlikely 
and a recent study assessing the global function of the hypothalamus in PD 
patients after DBS did not show any abnormalities of the hypothalamic-
adrenal, hypothalamic-gonadal and or hypothalamic-somatotropic axes.106 A 
stimulatory effect of the DBS electrode on fibre bundles projecting from or to 
the hypothalamic nuclei involved in the regulation of feeding behaviour and 
metabolism is a more plausible hypothesis, although the exact pathways 
remain to be elucidated. In PD patients with STN DBS, despite high leptin 
levels secondary to the weight gain, there is an increase of the orexigenic 
neuropeptide Y 107 108 and it has been hypothesized that DBS might make the 
hypothalamic neurons of the infundibular nucleus resistant to the 
anorexigenic effect of leptin.  
- Lateral hypothalamic area:. Only a few studies have explored the 
hypothalamic mechanisms of homeostatic regulation of feeding behaviour in 
patients with PD. Given the high prevalence of sleep abnormalities in PD 
patients, these studies have focused on the lateral hypothalamic area and 
orexin and MCH neuronal populations. These neurons play an important role 
in the sleep-wakefulness cycle and are also involved in energy and feeding 
regulation and its integration with arousal. Both neuronal populations are 
inhibited by leptin, activated by ghrelin and promote feeding . (Figure 2). As 
described previously, pathological studies have shown a severe reduction of 
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both neuronal populations in PD patients which correlates with disease 
severity,26 27 that could be involved in the pathogenesis of weight changes in 
PD patients.  
- Hedonic system:. Dysregulation of the dopaminergic mechanisms of 
hedonic control of feeding behaviour might also contribute to weight changes 
in PD. Although dopaminergic medications are generally reduced following 
STN DBS surgery, eating disorders secondary to behavioural changes 
following DBS may occur due to abnormalities on dopaminergic signalling 
similar to the alterations responsible for impulse control disorders, as 
proposed by some authors.82 The involvement of hedonic dysregulation in 
weight gain in PD is supported by changes in metabolism after DBS in brain 
areas including the orbito-frontal and anterior cingulate cortices using PET 
imaging.109      
 
Therapeutic implications 
Only a few studies have assessed nutritional interventions and therefore there is not 
strong evidence to give general recommendations. However, it is now well accepted 
that nutritional assessments should be part of the routine work-up of PD patients with 
PD and nutritional interventions may improve the PD associated related weight 
abnormalities. Individualised dietetic advice can improve nutritional status and quality 
of life in malnourished PD patients on medical treatment 110 and nutritional 
interventions have also been shown to be effective in weight control in patients with 
PD after DBS-STN surgery.111 Due to the interaction betweenin the small intenstine 
absorption in the small intestine betweenof L-dopa and amino acids[DB25], dietary 
interventions focusing on protein manipulation have been suggested in PD patients 
on treatment with L-dopa and motor fluctuations. WhilstThough there is not 
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enoughinsufficient evidence to support low-protein diets and they might induce 
weight loss and nutritional deficits in the long term, protein-redistribution interventions 
have shown an improvement in motor function with better results when carried out in 
early stages of the disease.112    
 
OSTEOPOROSIS AND BONE METABOLISM 
Patients with PD have an increased risk of fractures, most commonly involving 
affecting the hip.,113 and their oSubsequent clinical outcome tends to be poorer than 
in the rest of the population.114 A meta-analysis including nine studies showed a 
similar result, with a combined effect of the risk of fracture in patients with PD of 2.28 
(95%CI 1.83-2.83).113 Indeed, PD has been found to be the strongest single 
comorbidity contributing to fracture risk in the Global Longitudinal Study of 
Osteoporosis in Women cohort.115 Several causative factors have been implicated as 
responsible for the increased fracture risk in addition to the increased rate of falls 
intrinsic inherent to the disease itself (secondary to postural instability, gait freezing, 
cognitive impairment, orthostatic hypotension, and motor fluctuations and cognitive 
impairment). (Figure 3). Patients with PD have abnormalities of bone metabolism 
which also contributes to the increased risk of fractures. A meta-analysis concluded 
confirmed that patients with PD have significantly reduced bone mineral density at 
the femoral neck, lumbar spine, total hip and total body 113 in comparison with healthy 
controls. Using T-score values, the overall combined mean difference wasis 
significantly lower in patients with PD (-1.05; 95%CI -1.26 to -0.84).113 Immobility and 
reduced body mass index, both commonly seen in PD, are risk factors for 
osteoporosis but other several other factors disrupting bone metabolism may 
contribute to bone loss. 
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Role of vitamin D 
Vitamin D has a crucial role in bone metabolism and its deficiency results in bone 
loss by a compensatory hyperparathyroidism. The prevalence of vitamin D deficiency  
is significantly higher in PD patients with PD in comparisoncompared with healthy 
controls (up to 55% of patients in some studies) 116 117 and patients with other 
neurodegenerative conditions. 118 which This suggests that this is an intrinsic factor 
feature of the disease and not only a deficit secondary to reduced sunlight exposure. 
Vitamin D has also important effects on brain functioning and its receptors are 
strongly expressed in the dopaminergic neurons of the substantia nigra. 119 It has 
been hypothesized that a chronic vitamin D deficiency might contribute toin the 
pathogenesis of PD.120 The potential association of these two conditions is supported 
by the longitudinal study by Knekt et al 121 which showed that pre-existing vitamin D 
deficiency increased the risk of developing PD in a cohort of 3173 Finnish subjects 
after adjustment for potential confounders (patients with highest vitamin D 
concentration had a RR = 0.33; 95%CI 0.14-0.80 of developing PD in comparison to 
the patients with the lowest concentration). A possible link at transcriptional level has 
also been suggested, though studies looking for an association between some 
vitamin D receptor polymorphisms and the risk of PD have yielded conflicting results. 
122 In summary, whilst Though the potential pathogenic role of vitamin D deficiency in 
PD remains controversial, it is now generally recommended that vitamin D levels 
should be routinely checked and replaced if needed in all patients with PD for an 
adequate assessment of fracture risk.123 
 
Role of homocysteine  
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Hyperhomocysteinaemia is an independent risk factor for fractures through a dual 
mechanism reducing bone mineral density and disrupting cross-linking of collagen. 
124 Homocysteine has been shown to be elevated in L-dopa treated PD patients with 
PD in comparison tocompared with controls, but similar results were not found in 
drug naïve patients.125 Plasma levels correlate with disease severity and high 
concentrations showed an increased risk of hip fractures in PD patients (RR = 2.42; 
95%CI 1.21-3.63).126 The underlying mechanism causing hyperhomocysteinaemia in 
PD patients is not understood, however though L-dopa therapy and possibly vitamin 
B12 and folate deficiency might be implicated.124 125  
 
Therapeutic implications 
Despite the substantial fracture risk associated withto PD, bone health assessment 
and management have been largely ignored and no clinical guidelines address this 
issue specifically in PD patients. Taking into account these limitations, several 
recommendations can be made (Figure 3).  
- Fracture risk estimation:. FRAX [DB26]and Qfracture are useful tools to 
estimate fracture risk and guide those who should undergo dual X-ray 
absorptiometry (DEXA) for a more accurate evaluation of bone mineral 
density. FRAX assessment might be slightly superior in PD patients in the 
neurology clinic.127   
- Bisphosphonates:. It is unclear if patients withUntil evidence exists to 
support PD patients should havehaving a different DEXA threshold for anti-
osteoporotic therapy, so it seems reasonable to apply general population 
recommendations regarding treatment with bisphosphonates.123 Both 
risedronate and alendronate have demonstrated an improvement of bone 
mineral density and reduction of hip fractures in patients with PD.128-130  
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- Vitamin D:. Levels should be routinely measured in PD patients and replaced 
if deficient or insufficient. Vitamin D supplementation 131 and increased 
sunlight exposure 132 have both demonstrated an amelioration of 
hypovitaminosis D, an increase in bone mineral density levels and a reduction 
of the fracture risk in PD patients.  
- Non-pharmacological therapies:. An integrated approach including non-
pharmacological therapies such as exercise and lifestyle modifications should 
be included as part of a holistic care of PD.  
 
CONCLUSION    
Metabolic and neuroendocrine abnormalities are common in PD. They have been 
associated with multiple NMS and several studies have demonstrated their clinical 
implications. Clinicians should be aware of these implications abnormalities and 
include their assessment as part of routine clinical practice. Recognition and 
treatment of the neuroendocrine and metabolic disturbances in clinical practice will 
intuitively improve PD care and patients’ quality of life. The underlying 
pathophysiology of neuroendocrine disturbances in PD warrants further research. A 
better understanding of thise underlying pathogenesis will consequently lead to 
accurate peripheral biomarkers of these abnormalities and disease progression, and 
will enable the development of more effective targeted therapeutic interventions and 
neuroprotective drugs. 
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FIGURE LEGENDS 
Figure 1. Circadian system and its dysregulation in Parkinson’s disease. 
The circadian system is composed of a central pacemaker and peripheral oscillators. 
The SCN of the hypothalamus is the central pacemaker and its rhythmic activity is 
the result of the expression of several clock genes. It regulates the circadian rhythms 
of the peripheral oscillators by efferent neural and humoral signals (circulating 
melatonin). The SCN is entrained to the 24 hour environmental light cycle using the 
photic information received through the retino-hypothalamic tract and information on 
body functions through circulating melatonin and other time cues from peripheral 
oscillators. It also regulates melatonin secretion via an indirect multi- synaptic 
pathway reaching the pineal gland via the paraventricular nucleus of the 
hypothalamus and the superior cervical ganglion. Melatonin secretion during 
darkness is the main endogenous entraining agent of the circadian system exerting 
its function on peripheral oscillators and also a negative regulatory feedback on SCN 
activity. Main disruptions found in PD are shown in shaded boxes.  
AUC, area under the curve; PVN, paraventricular nucleus; RHT, retino-hypothalamic 
tract; SCG, superior cervical ganglion; SCN, suprachiasmatic nucleus. 
 
Figure 2. Feeding behaviour regulatory mechanisms and their dysregulation in 
Parkinson’s disease.  
Feeding behaviour is regulated by complex interactions between homeostatic and 
hedonic mechanisms. The hypothalamus is the central component of the 
homeostatic control with an interaction between both anorexigenic (CART and MSH 
neurons in the infundibular nucleus) and orexigenic signals (NPY and MSH 
synthesized by the infundibular nucleus and orexin and MCH neurons in the lateral 
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hypothalamic area). The activity of the hypothalamic neurons is influenced by 
peripheral humoral signals with opposite functions including circulating molecules, 
namely leptin (anorexigenic) and ghrelin (orexigenic), gut satiety peptides (CCK, 
OXM, PYY) and also levels of insulin, glucose or fatty acids. Leptin is an adipokine 
synthesized by the fat tissue reflecting the energy reserve and produces 
anorexigenic effects, whereas ghrelin, a peptide synthesized by the gastric mucosa 
during fasting, promotes feeding, weight gain and stimulates growth hormone 
secretion. The hedonic control (sensorial information, food reward systems) is 
integrated in several areas including the mesolimbic dopaminergic system, insular 
cortex, dorsal striatum, and anterior cingulate and orbitofrontal cortices. Main 
disruptions found in PD are shown in shaded boxes. Orexigenic areas are 
represented in diagonal line ovals and anorexigenic areas in white ovals.     
AgRP, agouti-related protein; CART, cocaine- and amphetamine-regulated transcript; 
CCK, cholecystokinin; DBS, deep brain stimulation; INF, infundibular nucleus; LHA, 
lateral hypothalamic area; MCH, melanin-concentrating hormone; MSH, melanocyte-
stimulating hormone; NA, nucleus accumbens; NPY, neuropeptide Y; OXM, 
oxyntomodulin; VTA, ventral tegmental area.  
 
Figure 3. Bone health assessment and management in PD patients. 
 
 
